

Hossein Haji Ali Afzali

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2489984/publications.pdf>

Version: 2024-02-01

34
papers

720
citations

567281

15
h-index

552781

26
g-index

34
all docs

34
docs citations

34
times ranked

1168
citing authors

#	ARTICLE	IF	CITATIONS
1	Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System. <i>Pharmacoeconomics</i> , 2018, 36, 239-252.	3.3	153
2	Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta-analysis. <i>Vaccine</i> , 2019, 37, 2768-2782.	3.8	121
3	When to Use Discrete Event Simulation (DES) for the Economic Evaluation of Health Technologies? A Review and Critique of the Costs and Benefits of DES. <i>Pharmacoeconomics</i> , 2014, 32, 547-558.	3.3	51
4	Improving the Accuracy and Comparability of Model-Based Economic Evaluations of Health Technologies for Reimbursement Decisions. <i>Medical Decision Making</i> , 2013, 33, 325-332.	2.4	31
5	The inpatient costs and hospital service use associated with invasive meningococcal disease in South Australian children. <i>Vaccine</i> , 2014, 32, 4791-4798.	3.8	31
6	A Critical Review of Model-Based Economic Studies of Depression. <i>Pharmacoeconomics</i> , 2012, 30, 461-482.	3.3	28
7	The Clinical Burden And Predictors of Sequelae Following Invasive Meningococcal Disease In Australian Children. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 316-318.	2.0	25
8	Exploring Structural Uncertainty in Model-Based Economic Evaluations. <i>Pharmacoeconomics</i> , 2015, 33, 435-443.	3.3	24
9	Community, parental and adolescent awareness and knowledge of meningococcal disease. <i>Vaccine</i> , 2014, 32, 2042-2049.	3.8	23
10	A conceptual framework for selecting the most appropriate variables for measuring hospital efficiency with a focus on Iranian public hospitals. <i>Health Services Management Research</i> , 2009, 22, 81-91.	1.7	21
11	Adolescent values for immunisation programs in Australia: A discrete choice experiment. <i>PLoS ONE</i> , 2017, 12, e0181073.	2.5	21
12	Model Performance Evaluation (Validation and Calibration) in Model-based Studies of Therapeutic Interventions for Cardiovascular Diseases. <i>Applied Health Economics and Health Policy</i> , 2013, 11, 85-93.	2.1	18
13	Practice nurse involvement in general practice clinical care: policy and funding issues need resolution. <i>Australian Health Review</i> , 2014, 38, 301.	1.1	18
14	Addressing the Challenge for Well Informed and Consistent Reimbursement Decisions. <i>Pharmacoeconomics</i> , 2011, 29, 823-825.	3.3	16
15	A proposed model for economic evaluations of major depressive disorder. <i>European Journal of Health Economics</i> , 2012, 13, 501-510.	2.8	16
16	Governments Need Better Guidance to Maximise Value for Money: The Case of Australiaâ€™s Pharmaceutical Benefits Advisory Committee. <i>Applied Health Economics and Health Policy</i> , 2016, 14, 401-407.	2.1	14
17	Model Structuring for Economic Evaluations of New Health Technologies. <i>Pharmacoeconomics</i> , 2018, 36, 1309-1319.	3.3	13
18	Adolescent confidence in immunisation: Assessing and comparing attitudes of adolescents and adults. <i>Vaccine</i> , 2016, 34, 5595-5603.	3.8	11

#	ARTICLE	IF	CITATIONS
19	Structuring a conceptual model for cost-effectiveness analysis of frailty interventions. PLoS ONE, 2019, 14, e0222049.	2.5	11
20	A Cost-Effectiveness Model for Frail Older Persons: Development and Application to a Physiotherapy-Based Intervention. Applied Health Economics and Health Policy, 2017, 15, 635-645.	2.1	10
21	Development and Use of Disease-Specific (Reference) Models for Economic Evaluations of Health Technologies: An Overview of Key Issues and Potential Solutions. Pharmacoeconomics, 2015, 33, 777-781.	3.3	8
22	Lifetime costs of invasive meningococcal disease: A Markov model approach. Vaccine, 2019, 37, 6885-6893.	3.8	8
23	Exploring health professionals' perspectives on factors affecting Iranian hospital efficiency and suggestions for improvement. International Journal of Health Planning and Management, 2011, 26, e17-29.	1.7	6
24	A Model-Based Economic Evaluation of Improved Primary Care Management of Patients with Type 2 Diabetes in Australia. Applied Health Economics and Health Policy, 2013, 11, 661-670.	2.1	6
25	Should the Lambda (λ) Remain Silent?. Pharmacoeconomics, 2016, 34, 323-329.	3.3	6
26	Practice nurse involvement in primary care depression management: an observational cost-effectiveness analysis. BMC Family Practice, 2014, 15, 10.	2.9	5
27	Improving Decision-Making Processes in Health: Is It Time for (Disease-Specific) Reference Models?. Applied Health Economics and Health Policy, 2020, 18, 1-4.	2.1	5
28	Is the Counterweight Program a feasible and acceptable option for structured weight management delivered by practice nurses in Australia? A mixed-methods study. Australian Journal of Primary Health, 2017, 23, 348.	0.9	4
29	The representation of public values in health technology assessment to inform funding decisions: the case of Australia's national funding bodies. International Journal of Technology Assessment in Health Care, 2021, 37, e22.	0.5	4
30	A model-based evaluation of collaborative care in management of patients with type 2 diabetes in Australia: an initial report. Australian Health Review, 2012, 36, 258.	1.1	4
31	Are the benefits of new health services greater than their opportunity costs?. Australian Health Review, 2019, 43, 508-510.	1.1	3
32	Expediting Patient Access to New Health Technologies: Role of Disease-Specific Reference Models. Value in Health, 2021, 24, 755-758.	0.3	3
33	The development of funding recommendations for health technologies at the state level: A South Australian case study. International Journal of Health Planning and Management, 2018, 33, 806-822.	1.7	1
34	Evaluation of collaborative models of care in the management of patients with depression: protocol and progress. Mental Health in Family Medicine, 2012, 9, 91-7.	0.2	1